0QT6.L - Genfit S.A.

LSE - LSE Prezzo differito. Valuta in EUR.
4,0040
+0,0535 (+1,35%)
Alla chiusura: 05:53PM BST
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente3,9505
Aperto3,8360
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno3,8940 - 3,9300
Intervallo di 52 settimane3,8940 - 3,9300
Volume1.481
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,93
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

    Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in multi-system disorders such as Acute-on-Chronic Liver Failure (ACLF)First-in-Human study planned in the second half of 2024 to support a Proof-of-Concept study in ACLF patients as early as 2025No material impact on previously guided cash runway: company funding rem

  • GlobeNewswire

    GENFIT: May 24, 2023 Combined Shareholders Meeting results

    Quorum of 29.54% on first convening; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 24, 2023. The quorum on first convening amo

  • GlobeNewswire

    GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 23, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology.1 NIS2+™ is a next-generation technology for the diagnosis of at-risk Non-Alcoholic Steatohepatitis (NASH). It is a non-invasive diagnostic tec

  • GlobeNewswire

    GENFIT Reports First Quarter 2023 Financial Information

    Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced its cash position as of March 31, 2023 and revenues for the first three months of 20231. Cash Position As of March 31, 2023, the Compan

  • GlobeNewswire

    GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is presenting Phase 1 clinical data evaluating NTZ as part of its Acute-on-Chronic Liver Failure (ACLF) Program at Digestive Disease Week®, taking place from May 6-9, 2023 in Chicago, Illinois (USA). The Phase 1, open-label c

  • GlobeNewswire

    GENFIT Announces Publication of Extra-Financial Performance Report 2022

    GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); April 27, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of its Extra-Financial Performance Report 2022. GENFIT’s Extra-Financial Performance Report in its second edition Since 2022, GENFIT has been

  • GlobeNewswire

    GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 19, 2023 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am (CET

  • GlobeNewswire

    GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC). T

  • GlobeNewswire

    GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

    Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024Transformative milestone expected towards end of second quarter 2023, with topline data readout for Phase 3 ELATIVE® evaluating elafibranor in primary biliary cholangitis (PBC) Multiple events in second quarter 2023: 1st patient screening in a Phase 2 study evaluating VS-01 in acute on-chronic liver failure (ACLF)1st patient screening in a Pha

  • GlobeNewswire

    GENFIT Announces Revenues and Cash Position as of December 31, 2022

    Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022. 1 2 Financials As of December 3

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the

  • GlobeNewswire

    GENFIT Announces 2023 Financial Calendar

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial

  • GlobeNewswire

    GENFIT to Participate in Upcoming Investor Conferences

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences. Conference Details (non-exhaustive list): Corporate Access Events during the 41st JPMorgan Healthcare ConferenceDate: January 8 – 12, 202

  • GlobeNewswire

    GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

    Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of actionA regular stream of new clinical data expected over the next few years across the spectrum of development stages (Phase 1, Phase 2, Phase 3)Aggregated global market size potential >$15bn1, distributed among acute on-chronic liver failure (ACLF) w

  • GlobeNewswire

    GENFIT Reports Third Quarter 2022 Financial Information

    Cash and cash equivalents: €163.6 million as of September 30, 2022 Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 2022 and revenue for the first nine months of 20221. Cash Position As of September 30, 2022, the Company’s cash and cash equivalents amounted to €163.6 million compared with

  • GlobeNewswire

    GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®

    NIS2+™ developed and validated as an optimization of NIS4® technology for the detection of patients with at-risk NASHData demonstrate robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-risk NASH, irrespective of patient characteristics such as age, sex and Type-2 diabetesNIS2+™’s analytical improvement allows for larger scale implementation in clinical practice and clinical trialsThree posters to be presented at AASLD Liver Meeting® Lille (France), Camb

  • GlobeNewswire

    GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

    Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG (“Versantis”) under the terms announced in its press release on September 19, 2022. As a result of this acquisition, GENFIT consolidates its position i

  • GlobeNewswire

    GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

    Financial highlights Cash and cash equivalents totaled €209 million as of June 30, 2022Net loss totaled €10 million for the first half 2022 Developments in our programs Patient enrollment for the double-blind part of the Phase 3 study in Primary Biliary Cholangitis (PBC) ELATIVETM completed at the end of the first semester 2022Orphan Drug Designation granted to GNS561 for the treatment of cholangiocarcinoma Agreement signed to acquire clinical-stage biotechnology company Versantis, further conso

  • GlobeNewswire

    GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

    Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE)Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthe

  • GlobeNewswire

    FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

    Lille (France), Cambridge (Massachusetts, United States), September 13, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma. Cholangiocarcinoma is a rare liver malignancy